Imunon, Inc.(IMNN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMNN Imunon, Inc.

Trading 06-26 12:25:40 EDT

1.77

+0.05

+2.91%

High1.85	Low1.71	Vol32.41K
Open1.73	D1 Closing1.72	Amplitude7.85%
Mkt Cap7.44M	Tradable Cap6.76M	Total Shares4.20M
T/O58.07K	T/O Rate0.85%	Tradable Shares3.82M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMNN","market":"US","secType":"STK","nameCN":"Imunon, Inc.","latestPrice":1.77,"timestamp":1782490997211,"preClose":1.72,"halted":0,"volume":32414,"delay":0,"changeRate":0.029069767441860492,"floatShares":3818399,"shares":4202100,"eps":-4.792268,"marketStatus":"Trading","change":0.05,"latestTime":"06-26 12:25:40 EDT","open":1.73,"high":1.845,"low":1.71,"amount":58074.559307,"amplitude":0.078488,"askPrice":1.83,"askSize":413,"bidPrice":1.79,"bidSize":73,"shortable":3,"etf":0,"ttmEps":-4.792268,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1782504000000},"marketStatusCode":2,"adr":0,"listingDate":959745600000,"exchange":"NASDAQ","adjPreClose":1.72,"preHourTrading":{"tag":"盘前","latestPrice":1.75,"preClose":1.72,"latestTime":"09:07 EDT","volume":244,"amount":426.8532096,"timestamp":1782479236772,"change":0.03,"changeRate":0.017442,"amplitude":0.01907},"postHourTrading":{"tag":"盘后","latestPrice":1.77,"preClose":1.72,"latestTime":"19:30 EDT","volume":853,"amount":1503.84,"timestamp":1782430243547,"change":0.05,"changeRate":0.02907,"amplitude":0.02907},"volumeRatio":1.450718},"requestUrl":"/m/hq/s/IMNN","defaultTab":"news","newsList":[{"id":"2645983939","title":"Imunon's Phase 3 Ovarian Cancer Trial Cleared to Continue","url":"https://stock-news.laohu8.com/highlight/detail?id=2645983939","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645983939?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:48","pubTimestamp":1782218890,"startTime":"0","endTime":"0","summary":"Imunon  said Tuesday an independent data monitoring committee recommended continuing the phase 3 trial evaluating its experimental therapy, IMNN-001, in combination with standard chemotherapy for women with advanced ovarian cancer, with no changes to the study.The company said the trial's primary endpoint is overall survival and includes two planned interim analyses that could support an accelerated marketing application if statistical significance is achieved early.The trial has enrolled 27 patients so far and Imunon said it expects to complete enrollment of about 80 patients by the end Q1 2027.Imunon shares were more than 7% higher in premarket trading.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","IMNN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645858839","title":"Imunon announces IDMC recommendation for continuation of OVATION 3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2645858839","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645858839?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:28","pubTimestamp":1782217728,"startTime":"0","endTime":"0","summary":"Imunon (IMNN) announced that the independent Data Monitoring Committee, or IDMC, has recommended continuation of the pivotal Phase 3 OVATION 3 clin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/imunon-announces-idmc-recommendation-for-continuation-of-ovation-3-trial-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/imunon-announces-idmc-recommendation-for-continuation-of-ovation-3-trial-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IMNN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645983517","title":"IMUNON says data monitoring committee backs continuing Phase 3 OVATION 3 ovarian cancer trial unchanged","url":"https://stock-news.laohu8.com/highlight/detail?id=2645983517","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645983517?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:00","pubTimestamp":1782216022,"startTime":"0","endTime":"0","summary":"Imunon’s independent monitoring committee recommended continuing the Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer.No new efficacy results were presented; the decision followed a safety and trial-conduct review with no changes to the study.The study targets overall survival as the primary endpoint, with interim looks intended to support a faster FDA filing if results are positive.Enrollment reached 27 patients; the company is targeting about 80 participants by the end of Q1 2027.The program is supported by prior Phase 2 results that indicated a survival benefit, without reporting new performance details.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL5kd0zL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B3QW5Z07.USD","SG9999014021.USD","BK4139","SG9999014005.SGD","IMNN","SG9999014039.USD","LU2210149790.SGD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","NDAQ","LU2210150020.SGD","BK4112","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU2095319765.USD","SG9999014013.SGD","BK4588","BK4585","IE00BKPKM429.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645354858","title":"Imunon Announces Data Monitoring Committee Recommends Continuation of Phase 3 Ovation 3 Study Without Modification","url":"https://stock-news.laohu8.com/highlight/detail?id=2645354858","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645354858?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:00","pubTimestamp":1782216005,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nTUA7JDWTZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMNN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645170835","title":"Imunon - Ovation 3 Trial on Track to Enroll 80 Patients by End of Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2645170835","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645170835?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:00","pubTimestamp":1782216005,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nTUA7JDWTZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMNN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645077760","title":"IMUNON CEO Stacy Lindborg to present at Life Sciences Investor Forum webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2645077760","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645077760?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:15","pubTimestamp":1782159342,"startTime":"0","endTime":"0","summary":"Imunon will present at the Life Sciences Investor Forum on June 25, 2026 at 12:00 p.m. ET.The session is scheduled as a live, interactive online event with real-time investor Q&A.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL6jkZkr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00BN0W2W23.USD","BK4588","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","IMNN","SG9999014013.SGD","IE00B64PRP62.GBP","LU2095319765.USD","LU2210149790.SGD","BK4112","SG9999014039.USD","BK4585","LU0314104364.USD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4139","SG9999014005.SGD","NDAQ","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644179332","title":"Imunon shareholders approve 1 million-share increase to 2018 stock incentive plan limit","url":"https://stock-news.laohu8.com/highlight/detail?id=2644179332","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644179332?lang=en_us&edition=fundamental","pubTime":"2026-06-17 05:30","pubTimestamp":1781645459,"startTime":"0","endTime":"0","summary":"Imunon held its annual shareholder meeting on June 16, 2026.Shareholders backed an amendment to the 2018 Stock Incentive Plan, lifting the plan’s share pool by 1,000,000 to 1,265,004 shares.The company’s auditor, WithumSmith + Brown, was ratified for the fiscal year ending Dec. 31, 2026.Director nominees Frederick J. Fritz, Christine A. Pellizzari received shareholder support for board service through the 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imunon Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 16, 2026, and is solely responsible for the informati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL8flGSS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640152227","title":"Imunon - Enters Securities Purchase Agreement With Streeterville Capital for $10 Mln Financing - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2640152227","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640152227?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:02","pubTimestamp":1780574525,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nFWN42C01S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMNN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640152123","title":"Imunon secures USD 10 million structured financing with preferred stock, promissory notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2640152123","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640152123?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:00","pubTimestamp":1780574440,"startTime":"0","endTime":"0","summary":"Imunon entered definitive agreements for USD 10 million gross proceeds via USD 2.5 million preferred stock issuance and USD 7.72 million in secured promissory notes.Notes total USD 7.72 million across two tranches of USD 2.72 million at 8% interest and USD 5 million at 5% interest.Promissory notes mature 18 months from issuance; interest partly offset by interest earned on bank deposits.Proceeds earmarked to support continued enrollment in the Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDLsY7cJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2210150020.SGD","BK4139","BK4112","IE00BN0W2W23.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014013.SGD","IE00B64PRP62.GBP","NDAQ","LU2210149790.SGD","SG9999014039.USD","LU0314104364.USD","IMNN","BK4585","SG9999014021.USD","SG9999014005.SGD","BK4588","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640152498","title":"Imunon Announces up to $10 Million Cash Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2640152498","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640152498?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:00","pubTimestamp":1780574404,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nTUAB4VTRJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMNN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635524099","title":"Analysts Are Bullish on Top Healthcare Stocks: Ovid Therapeutics (OVID), Imunon (IMNN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635524099","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635524099?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:10","pubTimestamp":1778616606,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ovid Therapeutics (OVID) and Imunon (IMNN) with bull...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-ovid-therapeutics-ovid-imunon-imnn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-ovid-therapeutics-ovid-imunon-imnn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4112","LU0128526141.USD","BLSX","BK4581","XBI","BK4588","BK4139","LABU","BK4585","BLSG","OVID","BK4137","LU0029874061.USD","IMNN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634219350","title":"Imunon Q1 net loss widens as R&D spending rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2634219350","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634219350?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:09","pubTimestamp":1778587755,"startTime":"0","endTime":"0","summary":"Imunon Q1 net loss widens as R&D spending risesOverviewU.S. biotech firm's Q1 net loss widened slightly as R&D spending increased for Phase 3 trialCompany advanced enrollment in pivotal Phase 3 OVATIO","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL1N41P0M1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMNN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634219856","title":"Imunon Q1 FY26 net loss widens to $4.3 million; cash drops to $4.8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634219856","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634219856?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:05","pubTimestamp":1778587503,"startTime":"0","endTime":"0","summary":"Imunon posted a first-quarter net loss of USD 4.3 million, or USD 0.84 per share, versus a net loss of USD 4.1 million, or USD 3.15 per share, a year earlier.Operating expenses rose to USD 4.3 million from USD 4.1 million, while R&D spending climbed to USD 2.3 million from USD 2.2 million.Net cash used in operating activities widened to USD 4 million from USD 2.8 million, reflecting trial-related costs tied to the Phase 3 OVATION 3 study.Cash and cash equivalents fell to USD 4.8 million as of March 31 from USD 8.8 million at year-end.Enrollment in OVATION 3 continued ahead of plan, with completion expected by Q1 2029; final Phase 2 OVATION 2 data showed median overall survival improved by 14.7 months to 45.1 months versus standard of care.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL4BVyDn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","BK4585","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4112","BK4139","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014039.USD","SG9999014013.SGD","LU2210150020.SGD","BK4588","IE00BKPKM429.USD","LU0314104364.USD","NDAQ","IMNN","LU2095319765.USD","SG9999014021.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634821641","title":"Imunon Q1 EPS $(0.84) Beats $(1.07) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2634821641","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634821641?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:01","pubTimestamp":1778587271,"startTime":"0","endTime":"0","summary":"Imunon (NASDAQ:IMNN) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(1.07) by 21.5 percent. This is a 73.33 percent increase over losses of $(3.15) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52481872/imunon-q1-eps-0-84-beats-1-07-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMNN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634216157","title":"Imunon Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2634216157","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634216157?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:00","pubTimestamp":1778587202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA5VQYW3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMNN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634921643","title":"Imunon Q1 Operating Income USD -4.307 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634921643","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634921643?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:00","pubTimestamp":1778587200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nPLXE44F46:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMNN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634161082","title":"Imunon Q1 EPS USD -0.84","url":"https://stock-news.laohu8.com/highlight/detail?id=2634161082","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634161082?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:00","pubTimestamp":1778587200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nPLXE44F46:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMNN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634421903","title":"IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2634421903","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634421903?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:00","pubTimestamp":1778587200,"startTime":"0","endTime":"0","summary":"IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment i","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3292797/0/en/IMUNON-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMNN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634361463","title":"Imunon Inc  expected to post a loss of $1.11 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634361463","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634361463?lang=en_us&edition=fundamental","pubTime":"2026-05-09 00:08","pubTimestamp":1778256486,"startTime":"0","endTime":"0","summary":"Imunon Inc  expected to post a loss of $1.11 a share - Earnings Preview Imunon Inc IMNN.OQ IMNN.O is expected to  show no change in quarterly revenue when it reports  results on May 12 for the period ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L20C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMNN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633948461","title":"Imunon schedules first-quarter results, business update conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2633948461","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633948461?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:33","pubTimestamp":1777984406,"startTime":"0","endTime":"0","summary":"Imunon set conference call for May 12, 2026 at 11:00 a.m. EDT to report Q1 2026 financial results.Business update expected to cover Phase 3 development progress for lead ovarian cancer candidate IMNN-001.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL1TW83G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","NDAQ","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014005.SGD","BK4112","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","IMNN","LU2210149790.SGD","LU2210150020.SGD","IE00BGHQF748.EUR","LU0314104364.USD","IE00B64PRP62.GBP","LU2095319765.USD","BK4585","BK4139","IE00BN0W2V16.EUR","SG9999014021.USD","BK4588","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.imunon.com","stockEarnings":[{"period":"1week","weight":-0.0549},{"period":"1month","weight":-0.2182},{"period":"3month","weight":-0.3676},{"period":"6month","weight":-0.454},{"period":"1year","weight":-0.8422},{"period":"ytd","weight":-0.5486}],"compareEarnings":[{"period":"1week","weight":-0.0167},{"period":"1month","weight":-0.0217},{"period":"3month","weight":0.158},{"period":"6month","weight":0.0637},{"period":"1year","weight":0.2095},{"period":"ytd","weight":0.0768}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.411765,"avgChangeRate":0.082435},{"month":2,"riseRate":0.363636,"avgChangeRate":0.03006},{"month":3,"riseRate":0.5,"avgChangeRate":0.046462},{"month":4,"riseRate":0.323529,"avgChangeRate":-0.048114},{"month":5,"riseRate":0.342857,"avgChangeRate":0.114856},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.056028},{"month":7,"riseRate":0.382353,"avgChangeRate":-0.054834},{"month":8,"riseRate":0.411765,"avgChangeRate":0.007426},{"month":9,"riseRate":0.294118,"avgChangeRate":-0.078238},{"month":10,"riseRate":0.294118,"avgChangeRate":-0.043613},{"month":11,"riseRate":0.294118,"avgChangeRate":-0.024039},{"month":12,"riseRate":0.441176,"avgChangeRate":-0.041409}],"exchange":"NASDAQ","name":"Imunon, Inc.","nameEN":"Imunon, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Imunon, Inc.(IMNN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Imunon, Inc.(IMNN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Imunon, Inc.,IMNN,Imunon, Inc.股票,Imunon, Inc.股票老虎,Imunon, Inc.股票老虎国际,Imunon, Inc.行情,Imunon, Inc.股票行情,Imunon, Inc.股价,Imunon, Inc.股市,Imunon, Inc.股票价格,Imunon, Inc.股票交易,Imunon, Inc.股票购买,Imunon, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Imunon, Inc.(IMNN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Imunon, Inc.(IMNN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction